Treatment with all-oral DAAs (SOF/LED) for 12 weeks was well tolerated in Egyptian children and adolescents infected with genotype 4 HCV, with 100% SVR12 and negligible side effects.

Hepatitis C virus (HCV) infection is one of the considerable health problems affecting huge number of population worldwide with a prevalence varying from 0.05%-0.36% in the United States and Europe. This ratio tends to be higher in developing countries especially in Egypt. 1 Egypt is a low-/middle-income country and was estimated to have the highest HCV prevalence rate in the world in 2013 and 5th highest number of HCV-infected individuals in 2017 2,3 with a prevalence rate of 14.7% and treatment costs amounting to around 1.4% of the gross national product 4,5 All six HCV genotypes are implicated in paediatric populations. 6 HCV genotype (GT)-4 represents 12%-15% (15-18 million) of the total global chronic HCV infection. 7 Its distribution has traditionally been confined to

No abstract

No abstract

No abstract